US Patent Issued to GMAX BIOPHARM on Nov. 18 for "Fusion protein of anti-eta antibody and tgf-beta trap and pharmaceutical composition and application thereof in method of treatment" (Chinese Inventors)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,473,369, issued on Nov. 18, was assigned to GMAX BIOPHARM LLC (Hangzhou, China).

"Fusion protein of anti-eta antibody and tgf-beta trap and pharmaceutical composition and application thereof in method of treatment" was invented by Cheng Zhang (Hangzhou, China), Chenjiang Yao (Hangzhou, China), Hua Zhang (Hangzhou, China), Xiaofeng Wang (Hangzhou, China) and Shuqian Jing (Hangzhou, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is a fusion protein of an ETA antibody and a TGF-Beta Trap. Also provided is a pharmaceutical composition of the fusion protein of the ETA antibody and the TGF-Beta Trap. Further provided is a method for treating, p...